Evidence map›Paper›PMID 37931970›Full record

ArticleBMJ open2023

How prevalent is COVID-19 vaccine hesitancy in low-income and middle-income countries and what are the key drivers of hesitancy? Results from 53 countries.

Julia Dayton Eberwein, Ifeanyi Nzegwu Edochie, David Newhouse, Alexandru Cojocaru, Gildas Deudibe Bopahbe, Jakub Jan Kakietek, Yeon Soo Kim, Jose Montes

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Julia Dayton EberweinWorld Bank Group, Washington, District of Columbia, USA jdayton@worldbank.org.ORCID 0000-0001-8936-6233
Ifeanyi Nzegwu EdochieWorld Bank Group, Washington, District of Columbia, USA.
David NewhouseWorld Bank Group, Washington, District of Columbia, USA.
Alexandru CojocaruWorld Bank Group, Washington, District of Columbia, USA.
Gildas Deudibe BopahbeWorld Bank Group, Washington, District of Columbia, USA.
Jakub Jan KakietekWorld Bank Group, Washington, District of Columbia, USA.
Yeon Soo KimWorld Bank Group, Washington, District of Columbia, USA.
Jose MontesWorld Bank Group, Washington, District of Columbia, USA.
World Bank Group · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to estimate the levels of COVID-19 vaccine hesitancy in 53 low-income and middle-income countries, differences across population groups in hesitancy, and self-reported reasons for being hesitant to take the COVID-19 vaccine.

methodsThis paper presents new evidence on levels and trends of vaccine hesitancy in low-income and middle-income countries based on harmonised high-frequency phone surveys from more than 120 000 respondents in 53 low-income and middle-income countries collected between October 2020 and August 2021. These countries represent a combined 53% of the population of low-income and middle-income countries excluding India and China.

resultsOn average across countries, one in five adults reported being hesitant to take the COVID-19 vaccine, with the most cited reasons for hesitancy being concerns about the safety of the vaccine, followed by concerns about its efficacy. Between late 2020 and the first half of 2021, there tended to be little change in hesitancy rates in 11 of the 14 countries with available data, while hesitancy increased in Iraq, Malawi and Uzbekistan. COVID-19 vaccine hesitancy was higher among female, younger adults and less educated respondents, after controlling for selected observable characteristics.

conclusionsCountry estimates of vaccine hesitancy from the high-frequency phone surveys are correlated with but lower than those from earlier studies, which often relied on less representative survey samples. The results suggest that vaccine hesitancy in low-income and middle-income countries, while less prevalent than previously thought, will be an important and enduring obstacle to recovery from the pandemic.

Indexed as

COVID-19COVID-19 VaccinesAdultChinaDeveloping CountriesFemaleHumansPovertyVaccinationCOVID-19 VaccinesCOVID-19Health policyPublic health

Identifiers

PMID37931970
PMCPMC10632876
OpenAlexW4388424784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.